secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001640334-22-001222
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension
---------------------------------------------------------------------------

- Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.
- AnodGen will pay royalties on revenues from sales of DehydraTECH-infused powders.
- Pre-IND meeting request filed with FDA for DehydraTECH-CBD for hypertension; target date July 30, 2022.
- IND-enabling development ongoing; Lexaria expects to submit IND in late 2022 or early 2023.
- HYPER-H21-4 study collects 24-hour BP, arterial stiffness, ECG, MRI, biomarkers, and other data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/0001640334-22-001222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-001222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer